Ventures Tour featuring a range of portfolio pitch sessions hosted by some of Cambridge’s most prominent venture capital ...

Iovance Biotherapeutics (NASDAQ: IOVA) didn't quite end the stock trading week on a high note. The company's shares were ...

Bio offers cryopreservation after death, aiming to revive bodies in the future—blending science with the age-old quest for immortality.

H.C. Wainwright raised the firm’s price target on IO Biotech (IOBT) to $14 from $12 and keeps a Buy rating on the shares following the Q1 report. The firm cites lower than expected operating expenses ...

Female entrepreneurs in the field of biotech, fashion, and beauty technology led workshops to give girls creativity, confidence, and ...

Primary endpoint of pivotal Phase 3 trial (IOB-013/KN-D18) of lead investigational therapeutic cancer vaccine in patients with advanced melanoma still expected to readout in third quarter of 2025Data ...

We recently published a list of 10 Best Low Priced Biotech Stocks to Buy Now. In this article, we are going to take a look at ...

As the cost-of-living crisis continues to squeeze household budgets, new research from Resume.io highlights the growing gap ...

Iovance Therapeutics’ stock dropped more than 44% on Friday afternoon, a day after the company slashed its 2025 sales ...

Iovance Biotherapeutics stock was tumbling Friday after the oncology drug maker posted a wider-than-expected first-quarter ...

However, that doesn't negate the long-term prospects of this beaten-down biotech stock. The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for ...

Despite a risk for severe side effects, pembrolizumab has a record of improving recurrence-free survival that makes it an ...